Oral Diet Pills Are Coming — Pills Instead of Injections

Wegovy and Mounjaro work. The problem: weekly injections. Needle phobia, elderly patients who can't self-inject, cost barriers — the race to make "diet pills" is intense.

Why Is Oral GLP-1 Hard?

GLP-1 is a peptide (amino acid chain) hormone. Swallowed as a pill:
1. Stomach acid destroys it: Proteins dissolve in HCl + pepsin
2. Can't absorb in intestine: Too large to cross gut wall
3. First-pass liver metabolism: Even if absorbed, liver breaks most of it down

Same reason insulin has been injection-only for 100 years.

Oral Obesity Drugs in Development

1. Oral Semaglutide High-Dose (Novo Nordisk)

Oral Wegovy launched in the US in January 2026. Once-daily pill, no refrigeration needed. 64-week trial: -16.6% weight loss (slightly better than injectable Wegovy's -14.9%).

How does a peptide survive stomach acid? SNAC technology:

1. SNAC locally raises pH around the pill (pH 5-6 shield in a few mm radius)
2. Temporarily loosens tight junctions between stomach lining cells
3. Semaglutide passes directly through stomach wall into capillaries

Bioavailability is only ~1% — 99% still gets destroyed. But the 50mg dose is ~20x the injectable dose (2.4mg), so that 1% is enough. Must take on empty stomach + fast 30 minutes after.

2. Orforglipron (Eli Lilly) — The Real Game-Changer

Orforglipron is a non-peptide small molecule GLP-1 agonist.

Why it matters:

• Small molecule → survives stomach acid

• Small molecule → easily absorbed in gut

• No SNAC enhancer needed

• Take with or without food

• Much cheaper to manufacture than peptides

Phase 2: 36 weeks → -14.7% at highest dose. Phase 3 results expected 2025.

If this succeeds, obesity treatment accessibility fundamentally changes.

3. CT-996 (Roche)

Another small molecule GLP-1. Phase 1: -6.1% in just 4 weeks (very fast).

4. MariTide (Amgen) — Different Approach

Not GLP-1. GIP receptor antagonist + activin receptor antibody. Aims to reduce fat while minimizing muscle loss (Wegovy/Mounjaro's biggest weakness). Monthly injection. Phase 2: -20% with better muscle preservation.

Why This Matters

Obesity affects ~13% of adults globally (WHO). The shift from "willpower" to "chronic disease requiring medication" is underway. Oral pills mean: no needle fear, lower production costs, billions of potential patients. 2025-2027 will be the watershed.